On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend from its 52-week high of $93.61, while still reflecting a subst

Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

Handelsbanken Fonder AB bought a new stake in Liquidia Corporation (NASDAQ: LQDA) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,000 shares of the company's stock, valued at approximately $1,993,000. Other institutional investors and hedge funds

Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.

YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus.

Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript

Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.